

Supplementary Table 1

Patient Number	Age Range	Race	Charlson Score	Day post-symptom onset on admission	Day post-symptom onset on first URT sample	Max SOFA	Max Oxygen Support	Discharged or Died
1	40-45	White	0	10	11	3	HFNC	Discharged
2	50-55	White	3	4	1	10	MV	Discharged
3	65-70	Black/African American	2	5	5	12	MV	Died
4	20-24	White	0	8	10	1	HFNC	Discharged
5	25-30	Black/African American	0	7	9	6	MV	Discharged
6	60-64	Asian	2	14	15	7	MV	Discharged
7	50-55	White	1	16	19	1	Nasal canula	Discharged
8	60-64	Asian	2	10	11	3	HFNC	Discharged

Table S1. Severe cohort description.

Supplementary Table 2

Patient	Remdesivir	Steroids	Tocilizumab
1	No	No	no
2	Yes	No	No
3*	Yes	Methylprednisolone	No
4	No	No	No
5	No	Methylprednisolone	Yes (disease day 11)
6	No	No	No
7	Yes	No	No
8	Yes	No	No

*Patient died

Table S2. Severe Patients Treatments.

Supplementary Table 3

Patient	Age Range	Race	Day post-symptom onset on first URT sample
1	20 - 25	Asian	5
2	30 - 35	White	1
3	20 - 25	White	2
4	36 - 40	White	5
5	20 - 25	White	7
6	55 - 60	White	16
7	26 - 30	White	6

Table S3. Mild Cohort Description.

Supplementary Table 4

Mild (first 10 days)			Mild (post-10 days)			Severe (first 10 days)			Severe (post-10 days)		
Patient	Viral Load (copies/ml)	Days post-symptoms onset	Patient	Viral Load (copies/ml)	Days post-symptoms onset	Patient	Viral Load (copies/ml)	Days post-symptoms onset	Patient	Viral Load (copies/ml)	Days post-symptoms onset
M1	2904472	5	M1	389	13	S2	239.56	1	S2	10483.64	11
M2	8708927	1					539.56	6		19053.49	12
	5637	8					77402.67	7		118.53	13
M3	4890344	2					1423569.87	8		3596.57	14
	414	9					872984.06	9		315.74	15
M4	8736696	5	M4	1366	11		1392050.16	10		402.69	16
M5	89208	7	M5	17790	14	S3	739.86	6	S3	641864.78	11
							57.81	7		42129.94	12
							2669499.66	8			
Average	3619385.429	5		6515	13		20231.51	9			
							10841.67	10			
						S4	105735.39	10	S4	3708253.04	11
										159890.78	12
										48123.28	14
										1988.38	14
										388.92	15
										53.72	16
						S5	3860244.05	9	S5	281038.61	11
										5863.65	12
										4114.9	13
										226967.07	14
										1160.12	15
										259.84	16
						Average	802625.8331	8		257803.3845	13

Table S4. Description of sample analyzed for pre and post day 10 comparisons

Supplementary Table 5

Marker*	CXCL10	DDX60	GBP1	HERC5	HERC6	IFIT5	OAS3	OASL	RTP4	SIGLEC1	SOCS1	SPATS2L	USP18	LAMP3 (higher in LRT severe)
URT (mild) correlation with	IFN-I Score	IFN-I Score	IFN-I Score	<i>IFNG</i>	IFN-I Score	IFN-I Score	IFN-I Score	ns	IFN-I Score	NfκB Score, <i>IFNA2</i>	IFN-I Score	NfκB Score, <i>IFNA2</i>	NfκB Score, <i>IFNA2</i>	ns
URT (severe) correlation with	IFN-I Score	ns	ns	ns	IFN-I Score	ns	IFN-I Score	ns	ns	ns	ns	ns	ns	ns
LRT (severe) correlation with	IFN-I Score, NfκB score, <i>IFNG</i> , negative corr <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNG</i> , negative corr <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNG</i> , negative corr <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNG</i> , negative corr <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNG</i> , negative corr <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNG</i> , negative corr <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNG</i> , negative corr <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	ns
Blood (severe) correlation with	NfκB score, <i>IFNA2</i> , <i>IFNB1</i>	IFN-I Score	NfκB score, <i>IFNB1</i>	IFN-I Score	IFN-I Score	IFN-I Score	IFN-I Score	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>	IFN-I Score, NfκB score, <i>IFNB1</i>
Function	Coordinates early adaptive immune responses through recruitment of CXCR3+ effector T and NK cells	Poorly defined	Poorly defined	Increases glycosylation		Negatively regulated by disrupting TBK1-IKKe-IRF3 signaling	Interferon-inducible antiviral proteins	Promotes antiviral activity by enhancing the sensitivity of RIG-I activation	Potent IFN-inducible inhibitor of human pathogens in the Flaviviridae	Siglec-1 functions as attachment receptor by enhancing ACE2-mediated infection	Regulated IFNAR1- but not IFNAR2-specific signals,	Involved in restricting viral entry and replication	Enforces viral replication in DCs	LAMP3 is one of about 400 genes that are activated by the integrated stress response (ISR) downstream of ATF4
Effect of low expression	Decreased might limit NK and T cell recruitment impairing recognition and clearance of SARS-CoV-2 infected cells			Reduced ISGylation increases viral stability		Reduced expression leads to stabilized and higher TBK1-IFFe-IRF3 function	Less degradation of viral RNA, inhibition of virus replication	Lack of RIG-I activity may impair the early restraining of SARS-CoV-2 infection in human lung cells.	Less genome amplification and viral production	Reduced Siglec1 in macrophages/D C may reduce viral uptake and infection	Poor regulation of type I interferon signaling and less beneficial antiviral versus detrimental proinflammatory effects.	Reduced SPATS2L leads to unreduced high SARS-CoV-2 RNA levels and viral entry and replication are less restricted	High USP18 early in infection in monocytes and DC may induce viral replication necessary to mount an effective TH1 and CD8+ T cell response respectively	Elevated levels are suggestive of an increased integrated stress response
Reference	1			2		3	4	5,6	7	8	9	10	11,12	13

* All markers were higher in URT swabs from patients with mild disease compared to the URT swabs from severe patients except for LAMP3 which was lower

References:

- Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, Stiles JK. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. *Cytokine Growth Factor Rev.* 2011 Jun;22(3):121-30. doi: 10.1016/j.cytogfr.2011.06.001. Epub 2011 Jul 29. PMID: 21802343; PMCID: PMC3203691.
- Mathieu NA, Papiaro E, Barr SD, Spratt DE. HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response. *Viruses.* 2021 Jun 9;13(6):1102. doi: 10.3390/v13061102. PMID: 34207696; PMCID: PMC8228270.
- Zhang N, Shi H, Yan M, Liu G. IFIT5 Negatively Regulates the Type I IFN Pathway by Disrupting TBK1-IKKe-IRF3 Signaling and Degrading IRF3 and IKKε. *Journal of Immunology (Baltimore, Md. : 1950).* 2021 May;206(9):2184-2197. DOI: 10.4049/jimmunol.2001033. PMID: 33858962.
- Bandy AR, Stanifer ML, Florez-Vargas O, Onabajo OO, Papenberg BW, Zahoor MA, Mirabello L, Ring TJ, Lee CH, Albert PS, Andrekos E, Arons E, Barsh G, Biessecker LG, Boyle DL, Brahier MS, Burnett-Hartman A, Carrington M, Chang E, Choe PG, Chisholm RL, Colli LM, Dalgard CL, Dude CM, Edberg J, Erdmann N, Feigelson HS, Fonseca BA, Firestein GS, Gehring AJ, Guo C, Ho M, Holland S, Hutchinson AA, Im H, Irby L, Ison MG, Joseph NT, Kim HB, Kreitman RJ, Korf BR, Lipkin SM, Mahgoub SM, Mohammed I, Paschoalini GL, Pacheco JA, Peluso MJ, Rader DJ, Redden DT, Ritchie MD, Rosenblum B, Ross ME, Anna HPS, Savage SA, Sharma S, Siouti E, Smith AK, Triantafyllia V, Vargas JM, Vargas JD, Verma A, Vij V, Wesemann DR, Yeager M, Yu X, Zhang Y, Boulant S, Chanock SJ, Feld JJ, Prokunina-Olsson L. Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. *Nat Genet.* 2022 Aug;54(8):1103-1116. doi: 10.1038/s41588-022-01113-z. Epub 2022 Jul 14. PMID: 35835913; PMCID: PMC9355882.
- Zhu J, Ghosh A, Sarkar SN. OASL-a new player in controlling antiviral innate immunity. *Curr Opin Virol.* 2015 Jun;12:15-9. doi: 10.1016/j.coviro.2015.01.010. Epub 2015 Feb 9. PMID: 25676874; PMCID: PMC4470762.
- Yamada T, Sato S, Sotoyama Y, et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. *Nat Immunol* 22, 820–828 (2021).
- Boys IN, Xu E, Mar KB, De La Cruz-Rivera PC, Eitson JL, Moon B, Schoggins JW. RTP4 Is a Potent IFN-Inducible Anti-flaviviral Effector Engaged in a Host-Virus Arms Race in Bats and Other Mammals. *Cell Host Microbe.* 2020 Nov 11;28(5):712-723.e9. doi: 10.1016/j.chom.2020.09.014. Epub 2020 Oct 27. PMID: 33113352; PMCID: PMC7666060.
- Lempp, F.A., Soriaga, L.B., Montiel-Ruiz, M. et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. *Nature* 598, 342–347 (2021). <https://doi.org/10.1038/s41586-021-03925-1>
- Fenner JE, Starr R, Cormish AL, Zhang JG, Metcalf D, Schreiber RD, Sheehan K, Hilton DJ, Alexander WS, Hertzog PJ. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. *Nat Immunol.* 2006 Jan;7(1):33-9. doi: 10.1038/ni1287. Epub 2005 Nov 27. PMID: 16311601.
- Martin-Sanchez L, Lewinski MK, Pache L, Stoneham CA, Yin X, Becker ME, Pratt D, Churas C, Rosenthal SB, Liu S, Weston S, De Jesus PD, O'Neill AM, Gounder AP, Nguyen C, Pu Y, Curry HM, Oom AL, Miorin L, Rodriguez-Frandsen A, Zheng F, Wu C, Xiong Y, Urbanowski M, Shaw ML, Chang MW, Benner C, Hope TJ, Frieman MB, Garcia-Sastre A, Ideker T, Hultquist JF, Guatelli J, Chanda SK. Functional landscape of SARS-CoV-2 cellular restriction. *Mol Cell.* 2021 Jun 17;81(12):2656-2668.e8. doi: 10.1016/j.molcel.2021.04.008. Epub 2021 Apr 13. PMID: 33930332; PMCID: PMC8043580.
- Honke N, Shaabani N, Zhang DE, Iliakis G, Xu HC, Häussinger D, Recher M, Löhning M, Lang PA, Lang KS. Usp18 driven enforced viral replication in dendritic cells contributes to break of immunological tolerance in autoimmune diabetes. *PLoS Pathog.* 2013 Oct;9(10):e1003650. doi: 10.1371/journal.ppat.1003650. Epub 2013 Oct 24. PMID: 24204252; PMCID: PMC3812017.
- Ritchie, K., Hahn, C., Kim, K. et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. *Nat Med* 10, 1374–1378 (2004). <https://doi.org/10.1038/nm1133>
- Burton TD, Fedele AO, Xie J, Sandeman LY, Proud CG. The gene for the lysosomal protein LAMP3 is a direct target of the transcription factor ATF4. *J Biol Chem.* 2020 May 22;295(21):7418-7430. doi: 10.1074/jbc.RA119.011864. Epub 2020 Apr 20. PMID: 32312748; PMCID: PMC7247307.

Table S5. Summary of the antiviral role of 13 genes with significant differences between mild and severe patients.